Severity and asthma management
| Cases (SLTA) | Matched hospital controls | Community comparison group | ||
|---|---|---|---|---|
| Severity | ||||
| Mild | 14% | 23% | 36%2-150 | |
| Moderate | 76% | 66% | 64%2-150 | |
| Severe | 9% | 11% | 0%2-150 | |
| Pharmacological management | ||||
| Inhaled β agonist | 98% | 100% | 99% | |
| Oral β agonist | 10% | 9% | 3% | |
| Other inhaled bronchodilator | 3% | 3% | 5% | |
| Oral theophylline | 44% | 21%2-150 | 6%2-160 | |
| Inhaled corticosteroids2-151 | ||||
| 0 | 32% | 26% | 44% | |
| <1000 μg | 35% | 37% | ||
| 1000–2000 μg | 19% | 20% | 56% | |
| >2000 μg | 13% | 16% | ||
| Cromolyn | 0% | 0% | 6% | |
| Possession of: | ||||
| Peak flow meter | 83% | 81% | ||
| Written action plan | 59% | 48% | ||
| Oral corticosteroid supply | 39% | 45% | ||
| Nebuliser | 35% | 26% | ||
| Inhaler technique checked (last year) | 54% | 46% | ||
| GP measured PEF | 84% | 78% | ||
| See doctor other than GP for asthma | 6% | 10% | ||